The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to CNP-106, an experimental treatment that Cour Pharmaceuticals is developing to reprogram the immune system in generalized myasthenia […] The post FDA grants orphan drug designation to CNP-106 for gMG appeared first on Myasthenia Gravis News.| Myasthenia Gravis News – The Web's Daily Resource for Myasthenia Gravis News
The FDA application followed trial results that showed NP-120 (ifenprodil) was well tolerated for idiopathic pulmonary fibrosis with cough.| Pulmonary Fibrosis News
SPG601, an oral treatment for fragile X syndrome that's now in clinical testing, has been granted orphan drug status in the European Union.| Fragile X News Today
Taladegib has been granted orphan drug designation in the U.S. and the European Union as a treatment for idiopathic pulmonary fibrosis.| Pulmonary Fibrosis News
The anti-inflammatory therapy telitacicept for myasthenia gravis was granted orphan drug status in the EU by the European Medicines Agency.| Myasthenia Gravis News
The FDA has granted orphan drug and rare pediatric disease designations to fragile X treatment KER-0193, Kaerus Biosciences said.| Fragile X News Today
An EU committee is recommending that tranilast, the active ingredient in a pulmonary fibrosis drug candidate, be awarded orphan drug status.| Pulmonary Fibrosis News
Investigational therapy BPN14770 has been granted orphan drug status by the U.S. Food and Drug Administration for the treatment of fragile X syndrome.| Fragile X News Today
